Huyen Thanh Nguyen1,2, Guang Jia1,
Zarine K. Shah1, Kamal S. Pohar3, Amir Mortazavi4,
Daniel Clark1, Mitva Patel1, Debra L. Zynger5,
Michael V. Knopp1,2
1Wright Center of
Innovation in Biomedical Imaging & Department of Radiology, the Ohio State
University, Columbus, OH, United States; 2Biophysics Program, the
Ohio State University, Columbus, OH, United States; 3Department of
Urology, the Ohio State University, Columbus, OH, United States; 4Department
of Internal Medicine, the Ohio State University, Columbus, OH, United States;
5Department of Pathology, the Ohio State University, Columbus, OH,
United States
The aim of this on-going study is to evaluate the usefulness of DCE-MRI in the assessment of neoadjuvant chemotherapeutic response of bladder cancer. A linear two-compartment pharmacokinetic model was used to calculate pharmacokinetic parameters and their maps. The results showed that DCE-MRI was able to increase significantly the accuracy of the assessment from 67% to 92%, reveal the changes in perfusion characteristics of bladder tumor due to the chemotherapy, and map out the responsive and non-responsive regions of bladder tumor. These promising results indicated that DCE-MRI is a reliable and powerful tool to assess and predict the neoadjuvant chemotherapeutic response of bladder cancer.
Keywords